-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, I39XcOc96gqkQvrhNaQxuwckxUnZZELKC/IhaF5AFnf1GBcfgAFc1t/lVj4psrej caqmoQImCW/e6714pi8qhA== 0000950162-04-000727.txt : 20040616 0000950162-04-000727.hdr.sgml : 20040616 20040615181859 ACCESSION NUMBER: 0000950162-04-000727 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040616 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ELAN PHARMACEUTICAL INVESTMENTS II LTD CENTRAL INDEX KEY: 0001256814 IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: CLAREDON HOUSE STREET 2: CHURCH STREET CITY: HAMILTON BERMUDA STATE: D0 ZIP: 00000 BUSINESS PHONE: 4412929169 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: DOV PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001066833 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223374365 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-78237 FILM NUMBER: 04864985 BUSINESS ADDRESS: STREET 1: 433 HACKENSACK AVENUE CITY: HACKENSACK STATE: NJ ZIP: 07601 BUSINESS PHONE: 2019680980 MAIL ADDRESS: STREET 1: 433 HACKENSACK AVENUE CITY: HACKENSACK STATE: NJ ZIP: 07601 SC 13G/A 1 dov13gano2061504.txt AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A2 Under the Securities Exchange Act of 1934 (Amendment No. 2)* DOV Pharmaceutical, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, par value $.0001 per Share - -------------------------------------------------------------------------------- (Title of Class of Securities) 259858108 - -------------------------------------------------------------------------------- (CUSIP Number) June 8, 2004 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: / / Rule 13d-1(b) / / Rule 13d-1(c) /X/ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP 259858108 SCHEDULE 13G -2- - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Elan Pharmaceutical Investments II, Ltd. - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) / / (b) / / - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Citizenship or Place of Organization Bermuda - -------------------------------------------------------------------------------- 5. Sole Voting Power 0 ----------------------------------------------------- Number of 6. Shared Voting Power Shares Beneficially 0 ----------------------------------------------------- Owned by Each 7. Sole Dispositive Power Reporting Person With: 0 ----------------------------------------------------- 8. Shared Dispositive Power 0 - -------------------------------------------------------------------------------- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 0 - -------------------------------------------------------------------------------- 10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) / / - -------------------------------------------------------------------------------- 11. Percent of Class Represented by Amount in Row (9) 0% - -------------------------------------------------------------------------------- 12. Type of Reporting Person (See Instructions) CO CUSIP 259858108 SCHEDULE 13G -3- Item 1(a). Name of Issuer: DOV Pharmaceutical, Inc. Item 1(b). Address of Issuer's Principal Executive Offices: 433 Hackensack Avenue, Hackensack, New Jersey 07601 Item 2(a). Name of Person Filing: This statement is filed on behalf of Elan Pharmaceutical Investments II, Ltd. (the "Reporting Person") Item 2(b). Address of Principal Business Office: Elan Pharmaceutical Investments II, Ltd. Clarendon House Church Street Hamilton, Bermuda Item 2(c). Citizenship: Elan Pharmaceutical Investments II, Ltd. is a Bermuda exempted limited liability company Item 2(d). Title of Class of Securities: Common Stock, par value $.0001 per share (the "Shares") Item 2(e). CUSIP Number: 259858108 Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or 240.13d-2(b) or (c), check whether the person is a: This Item 3 is not applicable Item 4. Ownership: (a) Amount beneficially owned: 0 (b) Percent of class: 0% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 0 (iv) shared power to dispose or to direct the disposition of: 0 CUSIP 259858108 SCHEDULE 13G -4- Item 5. Ownership of Five Percent or Less of a Class: This statement is being filed to report the fact that as of June 8, 2004 the reporting person has ceased to be a beneficial owner of more than five percent of the class of securities. Item 6. Ownership of More than Five Percent on Behalf of Another Person: Not Applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: Not Applicable Item 8. Identification and Classification of Members of the Group: Not Applicable Item 9. Notice of Dissolution of Group: Not Applicable Item 10. Certifications: Not Applicable. CUSIP 259858108 SCHEDULE 13G -5- SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: June 15, 2004 ELAN PHARMACEUTICAL INVESTMENTS II, LTD. By: /s/ Kevin Insley --------------------------------------- Name: Kevin Insley Title: Vice President -----END PRIVACY-ENHANCED MESSAGE-----